CSL and CSLLY Related Headlines
Go Back- CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
- EU panel recommends revoking Tavneos marketing authorization
- CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
- CSL announces expansion of Illinois plasma therapy manufacturing facility
- Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited
- Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
- CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
CSL and CSLLY Related Press Releases
Go Back- CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
- CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
- CSL announces expansion of Illinois plasma therapy manufacturing facility
- Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited
- Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
- CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
